EDITORIALS

347 To Treat or Not to Treat IgA Nephropathy? That Is the Question! Gerald B. Appel
See related article on page 467.

349 Depression in Patients with End-Stage Renal Disease Treated with Dialysis: Has the Time to Treat Arrived? Paul L. Kimmel and Rolf A. Peterson
See related article on page 496.

353 Intravenous Iron Therapy in Peritoneal Dialysis Patients: Short-Term Efficacy and Long-Term Issues Richard A. Zager
See related article on page 475.

356 Induction Therapy: Are We Picking Our Battles? Anil Chandraker and Stefan G. Tullius
See related article on pages 539 and 546.

IN-DEPTH REVIEW

358 Beyond Histology: Novel Tools to Diagnose Allograft Dysfunction Roslyn B. Mannon and Allan D. Kirk

MINI-REVIEWS

367 Can Hyperparathyroid Bone Disease Be Arrested or Reversed? Klaus Olgaard and Ewa Lewin

374 Histologic versus Molecular Diagnosis of BK Polymavirus-Associated Nephropathy: A Shifting Paradigm? Cinthia B. Drachenberg, John C. Papadimitriou, and Emilio Ramos

380 Dose of Dialysis in Acute Renal Failure Zaccaria Ricci, Rinaldo Bellomo, and Claudio Ronco


MOVING POINTS IN NEPHROLOGY

399 Antibodies Come Back to the Forefront in Transplantation Flavio Vincenti

400 Antibody Mediated Rejection: Update 2006 Paul Terasaki and Kazuo Mizutani

404 Mechanisms and Role of HLA and non-HLA Alloantibodies Kathryn J. Tinckam and Anil Chandraker

415 Antibody-Mediated Rejection in Renal Allografts: Lessons from Pathology Lorraine C. Racusen and Mark Haas

421 Presensitization: The Problem and Its Management Stanley C. Jordan and Mark D. Pescovitz

433 Sensitization after Kidney Transplantation Enver Akalin and Manuel Pascual

ORIGINAL ARTICLES

Acid/Base and Electrolyte Disorders

441 Increased Anion Gap Metabolic Acidosis as a Result of 5-Oxoproline (Pyroglutamic Acid): A Role for Acetaminophen Andrew Z. Fenves, Haskell M. Kirkpatrick, III, Viralkumar V. Patel et al.

Dialysis


455 Associations between Demographic Factors and Provider Structures on Cost and Length of Stay for Hemodialysis Patients with Vascular Access Failure Louis Brenner, Ajay K. Singh, Dennis Campbell et al.

Clinical Immunology and Pathology

462 Large Within-Day Variation in Cyclosporine Absorption: Circadian Variation or Food Effect? John J Curtis, Patsy Jones, and Ralph Barbeito

Table of Contents continued inside
### Clinical Nephrology

**467** Clinical Trial to Evaluate Omega-3 Fatty Acids and Alternate Day Prednisone in Patients with IgA Nephropathy: Report from the Southwest Pediatric Nephrology Study Group
Ronald J. Hogg, Jeannette Lee, Nancy Nardelli et al.  
See related editorial on page 347.

**475** Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized, Controlled Trial
Harneet Singh, John Reed, Sylvia Noble et al.; for the United States Iron Sucrose (Venofer) Clinical Trials Group  
See related editorial on page 353.

**483** Changing Incidence of Glomerular Disease in Olmsted County, Minnesota: A 30-Year Renal Biopsy Study
Sundaraman Swaminathan, Nelson Leung, Donna J. Lager et al.

**488** Exercise Performance Falls over Time in Patients with Chronic Kidney Disease Despite Maintenance of Hemoglobin Concentration
Murray J. Leikis, Michael J. McKenna, Aaron C. Petersen et al.

### Epidemiology and Outcomes

**496** Temporal Relation among Depression Symptoms, Cardiovascular Disease Events, and Mortality in End-Stage Renal Disease: Contribution of Reverse Causality
L. Ebony Boulware, Yongmei Liu, Nancy E. Fink et al.  
See related editorial on page 349.

**505** Septicemia in Patients with ESRD Is Associated with Decreased Hematocrit and Increased Use of Erythropoietin
Allen R. Nissenson, Michelle L. Dylan, Robert I. Griffiths et al.

**511** Steroid Treatment for Severe Childhood IgA Nephropathy: A Randomized, Controlled Trial
Norishige Yoshikawa, Masataka Honda, Kazumoto Iijima et al.; for the Japanese Pediatric IgA Nephropathy Treatment Study Group

**518** Relationship between Clinical Outcomes and Vascular Access Type among Hemodialysis Patients with *Staphylococcus aureus* Bacteremia
Jula K. Inrig, Shelby D. Reed, Lynda A. Szczek et al.

### Mineral Metabolism and Bone Disease

**525** Overproduction and Secretion of a Novel Amino-Terminal Form of Parathyroid Hormone from a Severe Type of Parathyroid Hyperplasia in Uremia
Toshio Arakawa, Pierre D'Amour, Louise Rousseau et al.

### Renal Transplantation

**532** Which Renal Transplant Candidates Should Accept Marginal Kidneys in Exchange for a Shorter Waiting Time on Dialysis?
Jesse D. Schold and Herwig-Ulf Meier-Kriesche

**539** Immunophenotypic Analysis of Cellular Infiltrate of Renal Allograft Biopsies in Patients with Acute Rejection after Induction with Alemtuzumab (Campath-1H)
Lorenzo Gallon, Elena Gagliardini, Ariela Benigni et al.  
See related editorial on page 356.

**546** Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cell–Targeted Therapy in Kidney Transplantation
Piero Ruggenenti, Igor Codreanu, Paolo Cravedi et al.  
See related editorial on page 356.

**555** Coronary Artery and Other Vascular Calcifications in Patients with Cystinosis after Kidney Transplantation
Masako Ueda, Kevin O’Brien, Douglas R. Rosing et al.

**563** Role of Maintenance Immunosuppressive Regimen in Kidney Transplant Outcome
Alexander S. Goldfarb-Rumyantsev, Lonnie Smith, Fuad S. Shihab et al.

**575** Hypoadiponectinemia Is Associated with Insulin Resistance and Glucose Intolerance after Renal Transplantation: Impact of Immunosuppressive and Antihypertensive Drug Therapy
Jøran Hjelmesæth, Allan Flyvbjerg, Trond Jenssen et al.

**583** Comparison of C4d Immunostaining Methods in Renal Allograft Biopsies
Megan L. Troxell, Lauren A. Weintraub, John P. Higgins et al.

### SPECIAL FEATURE

**592** The Nephrology Quiz and Questionnaire: 2005
Robert G. Narins